Vetter works towards a sustainable energy supply
All German sites of the pharmaceutical service provider will be supplied with green electricity.
Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources.
As a partner of biotechnology and pharmaceutical customers both large and small, Vetter has been meeting high international sustainability requirements for many years. The company is certified according to the standards for environmental protection ISO 14001, energy management ISO 50001, as well as occupational health and safety BS OHSAS 18001.
“Sustainability is a central pillar of Vetter’s corporate philosophy and our stance on this subject is firmly anchored within our organization. The supply of our German sites with green electricity is an important part of our company-wide program for environmental protection, energy management, and occupational health and safety,” explains Managing Director Thomas Otto. “Our aim is to act holistically and develop our multi-faceted initiatives in these areas on a continuous basis.”
The next milestone has already been set. Within the next 10 years, Vetter plans to offset the company-wide use of natural gas, making it completely CO2 neutral. Unavoidable CO2 emissions are offset by investments in high-quality climate protection projects.
The largest sustainability project the CDMO recently implemented is at its state-of-the-art center for visual inspection and logistics, which received the international industry prize Facility of the Year Award (FOYA) in 2018 as a Facility of the Future. The site consequently realizes a sustainable energy concept specifically developed by Vetter. This includes the operation of a modern, environmentally friendly block heating and power plant, the use of geothermal energy and the comprehensive use of excess energy, as well as powerful photovoltaic systems, all of which are combined in an energy-efficient manner.
The company-wide EHS program also includes actions for sustainable, resource-efficient management, the promotion of healthy working conditions, and regular training for all staff members to raise their individual awareness of responsible behaviour.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance